Lytenava (bevacizumab-vikg)

No published cost-effectiveness analysis, budget impact model, or health technology assessment of bevacizumab-vikg has been identified. Outlook Therapeutics established a U.S. wholesale acquisition cost of $485 per vial on September 16, 2026. As of the report date, bevacizumab-vikg had not yet launched commercially in the United States; the company has stated it expects to make the product available to eligible patients before the end of calendar 2026 and has described the potential to exceed $500 million in annual U.S. sales by 2030.